1 unchanged sentence
Evaluation of disclosure controls and procedures.
−Removed: Executive Officer (our principal executive officer) and our Interim Chief Financial Officer (our principal accounting officer) have evaluated our disclosure controls and procedures (as defined in Rules
−Removed: 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this annual report.
−Removed: Based on that evaluation, they have concluded
−Removed: that, as of the end of the period covered by this annual report, our disclosure controls and procedures were, in design and operation, effective at a reasonable assurance level.
+Added: Our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal accounting officer) have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this annual report.
+Added: Based on that evaluation, they have concluded that, as of the end of the period covered by this annual report, our disclosure controls and procedures were, in design and operation, effective at a reasonable assurance level.
Management’s Report on Internal Control Over Financial Reporting.
−Removed: Our management is responsible for
−Removed: establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended.
−Removed: Our management conducted an
−Removed: evaluation of the effectiveness of our internal control over financial reporting based on the 2013 framework in Internal ControlIntegrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.
−Removed: on its evaluation under the framework in Internal ControlIntegrated Framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2019.
+Added: Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended.
+Added: Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the 2013 framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.
+Added: Based on its evaluation under the framework in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2020.
Changes in internal control over financial reporting.
−Removed: There have not been any changes in our internal control
−Removed: over financial reporting during the quarter ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
+Added: There have not been any changes in our internal control over financial reporting during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent limitation on the effectiveness of internal control.
−Removed: The effectiveness of any system of internal
−Removed: control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct
+Added: The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely.
Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances.
−Removed: In addition, projections of any evaluation of
−Removed: effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
−Removed: We intend to continue to monitor and
−Removed: upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting
−Removed: This Annual Report does not include an attestation report of the Companys independent registered public accounting firm regarding internal control over
−Removed: financial reporting.
−Removed: Managements report was not subject to attestation by the Companys independent registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only
−Removed: managements report in this Annual Report.
+Added: In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
+Added: We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting
+Added: This Annual Report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting.
+Added: Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Annual Report.
Other Information.
−Removed: The information required by Part III is omitted from this report because we will file a definitive proxy statement within 120 days after the
−Removed: end of our 2019 fiscal year pursuant to Regulation 14A for our 2020 Annual Meeting of Stockholders, or the 2020 Proxy Statement, and the information to be included in the 2020 Proxy Statement is incorporated herein by reference.
+Added: The information required by Part III is omitted from this report because we will file a definitive proxy statement within 120 days after the end of our 2020 fiscal year pursuant to Regulation 14A for our 2021 Annual Meeting of Stockholders, or the 2021 Proxy Statement, and the information to be included in the 2021 Proxy Statement is incorporated herein by reference.
Directors, Executive Officers and Corporate Governance.
−Removed: (1) The information required by this Item concerning our executive officers and our directors and nominees for director, including information
−Removed: with respect to our audit committee and audit committee financial expert, may be found under the section entitled Proposal No.
−Removed: 1 Election of Directors, Information Regarding the Board of Directors and Corporate
−Removed: Governance, and Information About Our Executive Officers appearing in the 2020 Proxy Statement.
+Added: (1) The information required by this Item concerning our executive officers and our directors and nominees for director, including information with respect to our audit committee and audit committee financial expert, may be found under the section entitled “Proposal No.
+Added: 1 Election of Directors,” “Information Regarding the Board of Directors and Corporate Governance,” and “Information About Our Executive Officers” appearing in the 2021 Proxy Statement.
Such information is incorporated herein by reference.
−Removed: (2) The information required by this Item concerning our code of ethics may be found under the section entitled Information Regarding
−Removed: the Board of Directors and Corporate Governance appearing in the 2020 Proxy Statement.
+Added: (2) The information required by this Item concerning our code of ethics may be found under the section entitled “Information Regarding the Board of Directors and Corporate Governance” appearing in the 2021 Proxy Statement.
Such information is incorporated herein by reference.
−Removed: (3) The information required by this Item concerning compliance with Section 16(a) of the Securities Exchange Act of 1934 may be found in
−Removed: the section entitled Delinquent Section 16(a) Reports appearing in the 2020 Proxy Statement.
+Added: (3) The information required by this Item concerning compliance with Section 16(a) of the Securities Exchange Act of 1934 may be found in the section entitled “Delinquent Section 16(a) Reports” appearing in the 2021 Proxy Statement.
Such information is incorporated herein by reference.
Executive Compensation.
−Removed: The information required by this Item may be found under the sections entitled Director Compensation, Executive
−Removed: Compensation and Equity Compensation Plan Information appearing in the 2020 Proxy Statement.
+Added: The information required by this Item may be found under the sections entitled “Director Compensation,” “Executive Compensation” and “Equity Compensation Plan Information” appearing in the 2021 Proxy Statement.
Such information is incorporated herein by reference.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
−Removed: (1) The information required by this Item with respect to security ownership of certain beneficial owners and management may be found under the
−Removed: section entitled Security Ownership of Certain Beneficial Owners and Management appearing in the 2020 Proxy Statement.
+Added: (1) The information required by this Item with respect to security ownership of certain beneficial owners and management may be found under the section entitled “Security Ownership of Certain Beneficial Owners and Management” appearing in the 2021 Proxy Statement.
Such information is incorporated herein by reference.
−Removed: (2) The information required by this Item with respect to securities authorized for issuance under our equity compensation plans may be found
−Removed: under the sections entitled Equity Compensation Plan Information appearing in the 2020 Proxy Statement.
+Added: (2) The information required by this Item with respect to securities authorized for issuance under our equity compensation plans may be found under the sections entitled “Equity Compensation Plan Information” appearing in the 2021 Proxy Statement.
Such information is incorporated herein by reference.
Certain Relationships and Related Transactions, and Director Independence.
−Removed: (1) The information required by this Item concerning related party transactions may be found under the section entitled Transactions with
−Removed: Related Persons appearing in the 2020 Proxy Statement.
+Added: (1) The information required by this Item concerning related party transactions may be found under the section entitled “Transactions with Related Persons” appearing in the 2021 Proxy Statement.
Such information is incorporated herein by reference.
−Removed: (2) The information
−Removed: required by this Item concerning director independence may be found under the sections entitled Information Regarding the Board of Directors and Corporate GovernanceIndependence of the Board of Directors and Information
−Removed: Regarding the Board of Directors and Corporate GovernanceInformation Regarding Committees of the Board of Directors appearing in the 2020 Proxy Statement.
+Added: (2) The information required by this Item concerning director independence may be found under the sections entitled “Information Regarding the Board of Directors and Corporate Governance—Independence of the Board of Directors” and “Information Regarding the Board of Directors and Corporate Governance—Information Regarding Committees of the Board of Directors” appearing in the 2021 Proxy Statement.
Such information is incorporated herein by reference.
1 unchanged sentence
The information required by this Item may be found under the section entitled “Proposal No.
−Removed: 2 Ratification of Appointment of
−Removed: Independent Registered Public Accounting Firm appearing in the 2020 Proxy Statement.
+Added: 2 Ratification of Appointment of Independent Registered Public Accounting Firm” appearing in the 2021 Proxy Statement.
Such information is incorporated herein by reference.
Exhibits, Financial Statement Schedules.
−Removed: The following documents are filed as part of this report:
+Added: (a) The following documents are filed as part of this report:
(1) Financial Statements and Report of Independent Registered Public Accounting Firm
(2) Financial Statement Schedules
−Removed: Financial Statement Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the
−Removed: financial statements or notes thereto.
−Removed: Exhibits are incorporated herein by reference or are filed with this report as indicated below (numbered in
−Removed: accordance with Item 601 of Regulation S-K).
+Added: Financial Statement Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.
+Added: (3) Exhibits are incorporated herein by reference or are filed with this report as indicated below (numbered in accordance with Item 601 of Regulation S-K).
The exhibits listed below on the Exhibit Index are filed herewith or are incorporated by reference to exhibits previously filed with the SEC.
EXHIBIT INDEX
−Removed: Agreement and Plan of Merger by and between Aquinox Pharmaceuticals, Inc., Apollo Sub, Inc., and Neoleukin Therapeutics, Inc., dated August 5,
−Removed: 2019Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August 6, 2019
−Removed: Form of Support Agreement, by and among Aquinox Pharmaceuticals, Inc., Neoleukin Therapeutics, Inc.
−Removed: and each of the parties named in each agreement
−Removed: thereinIncorporated by reference to Exhibit 2.2 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August 6, 2019
−Removed: Form of Lock-Up
−Removed: Agreement, by each of the parties named in each agreement thereinIncorporated by reference to Exhibit 2.3 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August 6,
−Removed: Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc.Incorporated by reference to Exhibit 3.1 to our Current
−Removed: Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2014
−Removed: Amended and Restated Bylaws of Neoleukin Therapeutics, Inc.Incorporated by reference to Exhibit 3.6 to our Registration Statement on Form
−Removed: S-1, as amended (File No.
−Removed: 333-193615), filed with the Securities and Exchange Commission on February 28, 2014
−Removed: Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Stock, filed August
−Removed: 8, 2019Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August 12, 2019
−Removed: Certificate of Amendment to Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc., filed August
−Removed: 9, 2019Incorporated by reference to Exhibit 3.4 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission on November
−Removed: Certificate of Amendment to Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc., filed November
−Removed: 13, 2019Incorporated by reference to Exhibit 3.5 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission on November
+Added: Number Description
+Added: 2.1* Agreement and Plan of Merger by and between Aquinox Pharmaceuticals, Inc., Apollo Sub, Inc., and Neoleukin Therapeutics, Inc., dated August 5, 2019—Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August 6, 2019
+Added: 3.1 Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc.—Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2014
+Added: 3.2 Amended and Restated Bylaws of Neoleukin Therapeutics, Inc.—Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 13, 2020
+Added: 3.3 Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Stock, filed August 8, 2019—Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August 12, 2019
+Added: 3.4 Certificate of Amendment to Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc., filed August 9, 2019—Incorporated by reference to Exhibit 3.4 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission on November 13, 2019.
+Added: 3.5 Certificate of Amendment to Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc., filed November 13, 2019—Incorporated by reference to Exhibit 3.5 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission on November 13, 2019.
4.1 Specimen Common Stock Certificate of the Registrant—Incorporated by reference to Exhibit 4.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed with the Securities and Exchange Commission on May 13, 2014
−Removed: Registration Rights Agreement, dated September
−Removed: 19, 2016, by and between Aquinox Pharmaceuticals, Inc.
−Removed: and the persons listed on Schedule A attached theretoIncorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities
−Removed: and Exchange Commission on September 20, 2016
+Added: T able of C onten ts
+Added: Number Description
+Added: 4.2 Registration Rights Agreement, dated September 19, 2016, by and between Aquinox Pharmaceuticals, Inc.
+Added: and the persons listed on Schedule A attached thereto—Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on September 20, 2016
4.3 Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended
−Removed: Form of Pre-Funded WarrantIncorporated by reference to Exhibit 4.1 to our Current Report on Form
−Removed: 8-K filed with the Securities and Exchange Commission on December 19, 2019
−Removed: Exclusive Start-Up License Agreement, dated July
−Removed: 8, 2019, by and between the University of Washington and Neoleukin Therapeutics, Inc.Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission
−Removed: August 12, 2019
−Removed: Facility Use Agreement, dated December
−Removed: 4, 2018, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc.Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the Securities and Exchange Commission
−Removed: August 12, 2019
+Added: 4.4 Form of Pre-Funded Warrant—Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on December 19, 2019
+Added: 4.5 Form of Pre-Funded Warrant— Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 2, 2020.
+Added: 10.1 Exclusive Start-Up License Agreement, dated July 8, 2019, by and between the University of Washington and Neoleukin Therapeutics, Inc.—Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August 12, 2019
+Added: 10.2 Facility Use Agreement, dated December 4, 2018, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc.—Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August 12, 2019
10.3 Amendment No.
−Removed: 1 to the Facility Use Agreement, dated April
−Removed: 17, 2019, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc.Incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the Securities and Exchange Commission
−Removed: August 12, 2019
−Removed: Separation Agreement and Release, dated August
−Removed: 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and David J.
+Added: 1 to the Facility Use Agreement, dated April 17, 2019, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc.—Incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August 12, 2019
+Added: 10.4+ Separation Agreement and Release, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and David J.
Main—Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August 6, 2019
−Removed: Employment Agreement, dated August
−Removed: 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Jonathan G.
−Removed: DrachmanIncorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on
−Removed: August 6, 2019
−Removed: Transition Retention Agreement, dated August
−Removed: 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Kamran AlamIncorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August 6,
−Removed: Lease Agreement, dated September
−Removed: 23, 2019, by and between Neoleukin Therapeutics, Inc.
+Added: 10.5+ Transition Retention Agreement, dated August 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Kamran Alam—Incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August 6, 2019
+Added: 10.6 Lease Agreement, dated September 23, 2019, by and between Neoleukin Therapeutics, Inc.
and ARE-Eastlake Avenue No.
4 unchanged sentences
333-193615) filed with the Securities and Exchange Commission on January 28, 2014
−Removed: Forms of Option Agreement for Registrants Joint Canadian Stock Option PlanIncorporated by reference to Exhibit 10.2 to our Registration
−Removed: Statement on Form S-1 (File No.
+Added: 10.9+ Forms of Option Agreement for Registrant’s Joint Canadian Stock Option Plan—Incorporated by reference to Exhibit 10.2 to our Registration Statement on Form S-1 (File No.
333-193615) filed with the Securities and Exchange Commission on January 28, 2014
10.10+ Neoleukin Therapeutics, Inc.
−Removed: 2014 Equity Incentive Plan, as amended November
−Removed: 12, 2019Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on November 14, 2019
−Removed: Forms of Option Agreement and Option Grant Notice for Registrants 2014 Equity Incentive PlanIncorporated by reference to Exhibit 10.4
−Removed: to our Registration Statement on Form S-1 (File No.
+Added: 2014 Equity Incentive Plan, as amended November 12, 2019—Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on November 14, 2019
+Added: 10.11+ Forms of Option Agreement and Option Grant Notice for Registrant’s 2014 Equity Incentive Plan—Incorporated by reference to Exhibit 10.4 to our Registration Statement on Form S-1 (File No.
333-193615) filed with the Securities and Exchange Commission on January 28, 2014
−Removed: Form of Indemnity Agreement entered into between the Registrant and each of its directors and its executive officersIncorporated by reference
−Removed: to Exhibit 10.5 to our Registration Statement on Form S-1 (File No.
+Added: 10.12+ Neoleukin Therapeutics, Inc.
+Added: 2020 Employee Stock Purchase Plan—Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 6, 2020.
+Added: 10.13 Form of Indemnity Agreement entered into between the Registrant and each of its directors and its executive officers—Incorporated by reference to Exhibit 10.5 to our Registration Statement on Form S-1 (File No.
333-193615) filed with the Securities and Exchange Commission on January 28, 2014
−Removed: Exchange Agreement, dated December
−Removed: 17, 2019, by and among Neoleukin Therapeutics, Inc., 667, L.P.
−Removed: and Baker Brothers Life Sciences, L.P.Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and
−Removed: Exchange Commission on December 19, 2019
−Removed: Lease Agreement, dated February
−Removed: 5, 2016, by and between Aquinox Pharmaceuticals (Canada) Inc.
+Added: 10.14* Exchange Agreement, dated December 17, 2019, by and among Neoleukin Therapeutics, Inc., 667, L.P.
+Added: and Baker Brothers Life Sciences, L.P.—Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on December 19, 2019
+Added: T able of C onten ts
+Added: Number Description
+Added: 10.15 Lease Agreement, dated February 5, 2016, by and between Aquinox Pharmaceuticals (Canada) Inc.
and 560677 B.C.
Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2016
+Added: 10.16+ Executive Employment Agreement, dated March 16, 2020, Neoleukin Therapeutics, Inc.
+Added: and Robert Ho—Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission on May 6, 2020.
+Added: 10.17+ Amended and Restated Executive Employment Agreement, dated April 15, 2020, by and between Neoleukin Therapeutics, Inc., and Jonathan G.
+Added: Drachman—Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on April 17, 2020
+Added: 10.18 Underwriting Agreement, dated July 1, 2020, by and among Neoleukin Therapeutics, Inc., and BofA Securities, Inc.
+Added: and Piper Sandler & Co.
+Added: as Representatives of the several Underwriters named in Schedule A thereto— Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 2, 2020.
+Added: 10.19 First Amendment to Lease, dated June 18, 2020, by and between Neoleukin Therapeutics, Inc.
+Added: and ARE-Eastlake Avenue No.
+Added: 3, LLC—Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission on August 12, 2020.
+Added: 10.20+ Form of Restricted Stock Unit Grant Notice for Registrant’s 2014 Equity Incentive Plan— Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission on August 12, 2020
+Added: 10.21 Amendment No.
+Added: 1 to Exclusive Start-Up License Agreemen t, dated July 24, 2020 , by a nd between the University of Washington and Neoleukin Therapeutics, Inc.
+Added: 10.22 Executive Employment Agreement, dated September 29, 2020, by and between Neoleukin Therapeutics, Inc., and Holly Vance
+Added: 10.23 Purchase Order, dated November 25, 2020, by and between Neoleukin Therapeutics, Inc.
+Added: and Rigaku Americas Corporation
+Added: 10.24 First Amendment to Lease, dated November 5, 2020, by and between Neoleukin Therapeutics, Inc.
+Added: and ARE-Seattle No.
21.1 List of subsidiaries of the Registrant
+Added: 23.1 Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
23.2 Consent of Deloitte LLP, Independent Registered Public Accounting Firm.
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
−Removed: Certification of Interim Chief Financial Officer pursuant to Rule 13a-14(a).
+Added: 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a).
32.1# Certification of Chief Executive Officer pursuant to 18 U.S.C.
Section 1350.
−Removed: Certification of Interim Chief Financial Officer pursuant to 18 U.S.C.
+Added: 32.2# Certification of Chief Financial Officer pursuant to 18 U.S.C.
Section 1350.
−Removed: XBRL Instance Document
−Removed: XBRL Taxonomy Extension Schema Document.
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document.
−Removed: XBRL Taxonomy Extension Definition Linkbase Document.
−Removed: XBRL Taxonomy Extension Labels Linkbase Document.
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: 101.INS XBRL Instance Document
+Added: 101.SCH XBRL Taxonomy Extension Schema Document.
+Added: 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.
+Added: 101.DEF XBRL Taxonomy Extension Definition Linkbase Document.
+Added: 101.LAB XBRL Taxonomy Extension Labels Linkbase Document.
+Added: 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.
+ Indicates a management contract or compensatory plan.
−Removed: This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934,
−Removed: as amended (Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.
+Added: # This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.
* Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K.
A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.
+Added: T able of C onten ts
Form 10-K Summary.
−Removed: Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to
−Removed: be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Neoleukin Therapeutics, Inc.
−Removed: March 12, 2020
+Added: March 25, 2021 By:
/s/ Jonathan G.
1 unchanged sentence
(Principal Executive Officer)
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
−Removed: following persons on behalf of the registrant and in the capacities and on the dates indicated.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
+Added: Signature Title Date
/s/ Jonathan G.
−Removed: Director, President & Chief Executive Officer
−Removed: (Principal Executive Officer)
−Removed: March 12, 2020
−Removed: /s/ Kamran Alam
−Removed: Interim Chief Financial Officer
−Removed: (Principal Financial and Accounting Officer)
−Removed: March 12, 2020
−Removed: March 12, 2020
−Removed: /s/ Sean Nolan
−Removed: March 12, 2020
−Removed: /s/ Todd Simpson
−Removed: March 12, 2020
−Removed: March 12, 2020
+Added: Drachman Director, President & Chief Executive Officer
+Added: (Principal Executive Officer) March 25, 2021
+Added: /s/ Robert Ho Chief Financial Officer
+Added: (Principal Financial and Accounting Officer) March 25, 2021
+Added: /s/ Martin Babler Director March 25, 2021
+Added: Martin Babler
+Added: Cantey Boyd Director March 25, 2021
+Added: /s/ Erin Lavelle Director March 25, 2021
+Added: /s/ Sarah Noonberg Director March 25, 2021
+Added: Sarah Noonberg
+Added: /s/ Todd Simpson Director March 25, 2021
+Added: Williams Director March 25, 2021
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.